Department of Neurological Rehabilitation, Xuzhou Rehabilitation Hospital, Xuzhou, China.
Department of Rehabilitation, Xuzhou Central Hospital, Xuzhou, China.
Neurosci Lett. 2024 Mar 15;826:137732. doi: 10.1016/j.neulet.2024.137732. Epub 2024 Mar 14.
BACKGROUND: Alzheimer's disease (AD) is the primary reason for disability of the elderly. This article studied the diagnostic possibility of TUG1 and its potential mechanism in the regulation of aerobic exercise (AE) on AD. METHODS: 77 AD patients undertook a three-month-long cycling exercise, and 77 healthy controls were recruited. Polymerase Chain Reaction amplification was applied to assess the expression of TUG1 and miR-129-5p. The diagnostic possibility was manifested by the receiver operating characteristic (ROC) curve. Spearman correlation analyzed the interrelationships between TUG1 and AD. In vivo, the APP/PS1 double transgenic mouse models of AD were included for rescue experiments. Morris water maze (MWM) was performed to assess cognitive function of AD mice. RESULTS: The content of TUG1 was ascended in AD patients and was diminished after AE. The increase of TUG1 indicated the high risk of the occurrence of AD. TUG1 was closely connected to the cognitive assessment tools of AD patients. The TUG1/ miR-129-5p axis was the regulator of the regulation of AE in AD mice. CONCLUSION: TUG1 was involved in AD development and targeted miR-129-5p to participate in the regulation of AE.
背景:阿尔茨海默病(AD)是老年人残疾的主要原因。本文研究了 TUG1 的诊断可能性及其在有氧运动(AE)调节 AD 中的潜在机制。
方法:77 例 AD 患者接受了为期三个月的自行车运动,招募了 77 名健康对照者。聚合酶链反应扩增用于评估 TUG1 和 miR-129-5p 的表达。通过接受者操作特征(ROC)曲线来表现 TUG1 的诊断可能性。Spearman 相关性分析了 TUG1 与 AD 之间的相互关系。在体内,包括 AD 的 APP/PS1 双转基因小鼠模型进行了挽救实验。Morris 水迷宫(MWM)用于评估 AD 小鼠的认知功能。
结果:AD 患者的 TUG1 含量升高,AE 后降低。TUG1 的增加表明 AD 发生的风险较高。TUG1 与 AD 患者的认知评估工具密切相关。TUG1/miR-129-5p 轴是 AD 小鼠 AE 调节的调节剂。
结论:TUG1 参与 AD 的发展,并靶向 miR-129-5p 参与 AE 的调节。
Neuroimmunomodulation. 2022
Front Biosci (Landmark Ed). 2024-8-21
Dement Geriatr Cogn Disord. 2020
Am J Alzheimers Dis Other Demen. 2022
Transl Psychiatry. 2025-4-11
Signal Transduct Target Ther. 2024-5-29